Mark Freedman shares what he considers to be the most promising areas of MS research and his highlights from ECTRIMS-ACTRIMS 2017. Part 2 of 2.
View Part 1 here.
1. What are the most promising areas of MS research? (0:05)
2. Which presentations/data at ECTRIMS–ACTRIMS have interested you the most? (2:27)
Speaker disclosures: Mark Freedman has received honoraria or consultation fees from Bayer Healthcare, Biogen-Idec, Chugai, EMD Canada, Genzyme, Novartis, Sanofi-Aventis and Teva Canada Innovation. He is a member of the following company advisory boards, board of directors or other similar group for Bayer Healthcare, Biogen-Idec, Hoffman La-Roche, Merck Serono, Novartis, Opexa and Sanofi-Aventis. He is a participant in Genzyme’s company-sponsored speaker’s bureau.
Filmed at the 7th Joint ECTRIMS-ACTRIMS Meeting, Paris, France, October 2017.
